Among the most promising therapeutic options for individuals with coronavirus disease 2019 (COVID-19) are monoclonal antibodies (mAbs). In this study, Jones et al . identified, characterized, and tested one such mAb, LY-CoV555, in vitro and in vivo. They found that LY-CoV555 bound to the severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) spike protein and prevented its interaction with angiotensin-converting enzyme 2. Prophylactic treatment with LY-CoV555 protected the upper and lower respiratory tracts of nonhuman primates from becoming infected with SARS-CoV-2. Together, these data support the clinical use of LY-CoV555 for treating patients with COVID-19.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less res
The U.S. new cases 7-day rolling average are 4.8 % LOWER than the 7-day rolling average one week ago and U.S. deaths due to coronavirus are now 15.2 %
LOWER than the rolling average one week ago. Today s posts include:
U.S. Coronavirus New Cases are 54,434
U.S. Coronavirus deaths are at 1,245
U.S. Coronavirus immunizations have been administered to 33.1 % of the population
The 7-day rolling average rate of growth of the pandemic shows new cases worsened and deaths improved
What we know about India s Covid-19 vaccine
AstraZeneca Vax Flops Against South African Variant in Early Trial
Some long-haul covid-19 patients say their symptoms are subsiding after getting vaccines